Reason for request
Favourable opinion for reimbursement in the treatment of moderate to severe atopic dermatitis in adolescents 12 years and older who are candidates for systemic therapy.
What therapeutic improvement?
Therapeutic improvement in management.
Role in the care pathway?
The overall objective of treatment in patients with atopic dermatitis is to improve their quality of life by treating their skin lesions and preventing the risk of secondary infections in the event of flare-ups, early relapses and xeroderma. Outside inflammatory flare-ups, all patients should be treated using adjuvant measures (hygiene, emollients) and relapses should be treated at an early stage.
The treatment of inflammatory flare-ups in mild to moderate atopic dermatitis is based on the use of topical corticosteroids.
In children and adolescents, the clinical benefit of tacrolimus (PROTOPIC) in the event of an inadequate response or intolerance (risk of skin atrophy) to well-managed topical corticosteroid treatment has been judged to be insufficient.
Light therapy is used in exceptional cases only in adolescents.
In the event of severe atopic dermatitis or non-response to topical treatments and light therapy, systemic immunosuppressant treatments are used. Ciclosporin is proposed in adolescents in the guidelines. However, its MA does not recommend its use in patients under the age of 16 years in atopic dermatitis due to limited experience and data in this indication (see SPC).
Other immunosuppressant agents, such as methotrexate, azathioprine and mycophenolate mofetil, are proposed in refractory atopic dermatitis, but this use is off-label. In the paediatric population, these treatments are little used due to their toxicity and they cannot be administered long term.
Role of the medicinal product in the care pathway
DUPIXENT (dupilumab) is a second-line treatment to be reserved for moderate to severe forms of atopic dermatitis in adolescents in whom topical treatment has failed.
The clinical benefit of the proprietary medicinal products DUPIXENT 200 mg and 300 mg (dupilumab) is substantial in the indication “treatment of moderate to severe atopic dermatitis in adolescents 12 years and older who are candidates for systemic therapy” and at the MA dosages.
Clinical Added Value
with a significant and clinically relevant additional effect size,
The proprietary medicinal products DUPIXENT 200 mg and 300 mg (dupilumab) provide a moderate clinical added value (CAV III) in the treatment of moderate to severe atopic dermatitis in adolescents 12 years and older who are candidates for systemic therapy.